Additional Immunotherapy to Standard of Care for Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
Oncology Research and Treatment · 15.05.2025 · 48 (11) · 740-752
DOI: 10.1159/000546407 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Oncology Research and Treatment, online erschienen am 15.05.2025. Verfasst von Wanfang Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taikang Tongji (Wuhan) Hospital, Wuhan, China. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Introduction
The role of immunotherapy in the treatment of locally advanced head and neck squamous cell carcinoma (LA HNSCC) remains uncertain, particularly in cases of unresectable LA HNSCC. This meta-analysis aimed to evaluate the efficacy of immunotherapy in patients with unresectable LA HNSCC through a systematic review of the existing literature.
Methods
This meta-analysis followed a registered protocol on the INPLASY platform with the registration number INPLASY202510102. We systematically collected studies that compared the combination of immunotherapy and standard of care (SOC) with SOC alone for patients with unresectable LA HNSCC. Review Manager, Stata, and R software were employed to conduct single-group rate meta-analysis, pairwise meta-analysis, and Bayesian network meta-analysis.
Results
A meta-analysis of fifteen eligible studies involving 3,055 patients revealed no significant improvement in progression-free survival (PFS) or overall survival (OS) with the addition of immunotherapy. Specifically, in patients with human papilloma-positive (HPV+) LA HNSCC, the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT) resulted in 2-year PFS and OS rates of 93% and 97%, respectively. In contrast, LA HNSCC patients treated with chemoradiotherapy followed by sequential pembrolizumab exhibited 2-year PFS and OS rates of 89% and 94%, respectively. Furthermore, our study demonstrated that the combination of pembrolizumab and CCRT achieved a higher 2-year PFS rate compared to the combination of avelumab and CCRT.
Conclusion
Although the addition of immunotherapy to SOC regimens did not result in a survival benefit, patients with HPV+ unresectable LA HNSCC may potentially derive benefit from immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Taikang Tongji (Wuhan) Hospital, Wuhan, China.
- Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Hubei Key Laboratory of Tumor Biological Behavior, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Oral and Maxillofacial Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan, China.
Zitieren
APA
Zhang, W., Li, S., Zhang, N., Bu, L., & Wu, Q. (2025). Additional Immunotherapy to Standard of Care for Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Oncology Research and Treatment, 48(11), 740-752. https://doi.org/10.1159/000546407
Vancouver
Zhang W, Li S, Zhang N, Bu L, Wu Q. Additional Immunotherapy to Standard of Care for Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Oncology Research and Treatment. 2025;48(11):740-752. doi:10.1159/000546407
BibTeX
@article{Zhang2025,
author = {Zhang, Wanfang and Li, Shaojie and Zhang, Ni and Bu, Linlin and Wu, Qiuji},
title = {Additional Immunotherapy to Standard of Care for Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis},
journal = {Oncology Research and Treatment},
year = {2025},
volume = {48},
number = {11},
pages = {740--752},
doi = {10.1159/000546407}
}
EUVIMED